FDA
-
-
-
-
-
-
-
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
vTv Therapeutics to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
-
-
-
-
-
-
-
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes
-
-
-
-
-
-
-
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
vTv Therapeutics (VTVT) Reports Q2 Results
-
329,911 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

